Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5284548 | 1.00 | KCNH2 (0.37) | KCNH2SCN5AKDM4EALDH1A1HPGD | |
| SCHEMBL5570849 | 0.89 | KCNH2 (0.36) | KCNH2SCN5AKDM4EALDH1A1HPGD | |
| SCHEMBL14497297 | 0.89 | KCNH2 (0.36) | KCNH2SCN5AKDM4EALDH1A1HPGD | |
| SCHEMBL5570851 | 0.89 | KCNH2 (0.36) | KCNH2SCN5AKDM4EALDH1A1HPGD | |
| SCHEMBL8569539 | 0.89 | SCN5A (0.44) | KCNH2SCN5AKDM4EALDH1A1HPGD | |
| SCHEMBL8575664 | 0.89 | SCN5A (0.44) | KCNH2SCN5AKDM4EALDH1A1HPGD | |
| SCHEMBL8565377 | 0.89 | SCN5A (0.44) | KCNH2SCN5AKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL8575905 | 0.88 | SCN5A (0.43) | KCNH2SCN5AKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL8569538 | 0.88 | SCN5A (0.43) | KCNH2SCN5AKDM4EALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL8577938 | 0.88 | SCN5A (0.43) | KCNH2SCN5AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229996-B2 | Rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1781670-A1 | RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS | Cumbre Pharmaceuticals Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006012470-A1 | RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS | CUMBRE PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019985-A1 | Rifamycin derivatives | CUMBRE INC. (US) | 2006-01-26 | — | — | US | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019985-A1 | Rifamycin derivatives | RIF1, NQO1, MRM1 | KCNH2 2117/4885SCN5A 2077/4885KDM4E 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.